Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/39884
Title: | Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain. | |
Authors: | ||
Keywords: | ||
Issue Date: | 2017 | |
Citation: | Clinicoecon Outcomes Res.2017;(9):127-137 | |
Abstract: | The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. | |
PMID: | 28228660 | |
URI: | https://hdl.handle.net/20.500.12530/39884 | |
Rights: | openAccess | |
ISSN: | 1178-6981 | |
Appears in Collections: | Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos | |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PMC5312689.pdf | 228.41 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.